SK Bioscience Co Ltd (302440) - Total Liabilities
Based on the latest financial reports, SK Bioscience Co Ltd (302440) has total liabilities worth ₩847.96 Billion KRW (≈ $574.65 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
SK Bioscience Co Ltd - Total Liabilities Trend (2018–2024)
This chart illustrates how SK Bioscience Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See 302440 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
SK Bioscience Co Ltd Competitors by Total Liabilities
The table below lists competitors of SK Bioscience Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Northern Oil & Gas Inc
NYSE:NOG
|
USA | $3.73 Billion |
|
Suzhou Victory Precision Manufacture Co Ltd
SHE:002426
|
China | CN¥4.18 Billion |
|
Cimpress NV
NASDAQ:CMPR
|
USA | $2.51 Billion |
|
OCADO GROUP SP.ADR 1/2
F:0OC1
|
Germany | €2.72 Billion |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436
|
China | CN¥1.10 Billion |
|
China Nonferrous Metal Industry’s Foreign Engineering and Construction Co Ltd
SHE:000758
|
China | CN¥13.69 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $156.37 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down SK Bioscience Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 302440 market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.46 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SK Bioscience Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SK Bioscience Co Ltd (2018–2024)
The table below shows the annual total liabilities of SK Bioscience Co Ltd from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩821.14 Billion ≈ $556.48 Million |
+452.65% |
| 2023-12-31 | ₩148.58 Billion ≈ $100.69 Million |
-62.88% |
| 2022-12-31 | ₩400.23 Billion ≈ $271.23 Million |
-21.34% |
| 2021-12-31 | ₩508.81 Billion ≈ $344.81 Million |
+70.49% |
| 2020-12-31 | ₩298.44 Billion ≈ $202.25 Million |
+74.28% |
| 2019-12-31 | ₩171.25 Billion ≈ $116.05 Million |
-10.80% |
| 2018-12-31 | ₩191.98 Billion ≈ $130.10 Million |
-- |
About SK Bioscience Co Ltd
SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the preve… Read more